Accessibility Menu
Alzamend Neuro logo

Alzamend Neuro

(NASDAQ) ALZN

Current Price$1.25
Market Cap$4.60MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-100%
5 Year-100%
1 Year-65%
1 Month-3%
Alzamend Neuro last closing stock price
MetricPriceDate
Last closeUSD 1.212026-07-17
Alzamend Neuro stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.54%USD 1.182026-07-10
1 month-3.2%USD 1.252026-06-17
3 month+8.04%USD 1.122026-04-17
Year to date-33.52%USD 1.822025-12-31
1 year-64.62%USD 3.422025-07-17
3 year-99.83%USD 693.232023-07-18
5 year-99.99%USD 8,329.502021-07-16
Since inception-99.99%USD 18,224.992021-06-15

Alzamend Neuro Financials at a Glance

Market Cap

$4.60MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$7.04M

EPS (TTM)

-$4.38

P/E Ratio

-0.28

Dividend

$0.00

Beta (Volatility)

1.05 (Average)

Price

$1.25

Volume

57,047.617

Open

$1.20

Previous Close

$1.26

Daily Range

$1.18 - $1.28

52-Week Range

$0.84 - $3.35

Estimated Earnings Date

Jul 28, 2026

ALZN News

Medical researchers - GettyImages-1213006106

Why Alzamend Neuro Stock Soared Today

Joe TenebrusoDec 14, 2021
falling chart held up by businessman

Why Alzamend Neuro Stock Fell More Than 14% Today

James BrumleyJul 26, 2021
scientists-at-work-in-laboratory

Here's Why Alzamend Neuro Stock Is Shooting Higher Today

Cory RenauerJul 23, 2021

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Alzamend Neuro

Alzamend develops medicines for brain and mental health conditions. Its products aim to help people with Alzheimer’s and mood disorders. The company focuses on treatments that may improve daily life for patients and families.

Brainy Business: Products and Services

  • AL001 (0% revenue): Oral medicine combining lithium, proline, and salicylate for Alzheimer’s, bipolar disorder, depression, and PTSD.
  • ALZN002 (0% revenue): Cell-based vaccine using a patient’s immune cells to target Alzheimer’s disease.
  • Clinical Research: Focused on early-stage trials for neurodegenerative and psychiatric disorders.
  • Licensing: All core technologies licensed from the University of South Florida Research Foundation.

Growth Spurts: Expansion and Partnerships

  • Launched Phase II trial for AL001 in May 2025 with Massachusetts General Hospital as research partner.
  • Started Phase I/IIA trial for ALZN002 in April 2023; seeking new research partner after ending contract with Biorasi.
  • Expanded AL001 research to compare with standard lithium treatments in 2025.
  • Ongoing efforts to broaden AL001’s uses and delivery methods since 2024.

What Makes Alzamend Stand Out

Alzamend holds exclusive global licenses for its drug technologies, offering potential market protection. Its lead product aims to reduce lithium’s side effects, which is important for elderly patients. The company partners with major research hospitals to run clinical trials.

Five Things You Need to Know

  • No revenue reported for Q1 2026, Q1 2025, or Q1 2024.
  • Net loss was $3 million in Q1 2026, down 177.5% from Q1 2025.
  • Cash was $5 million in Q1 2026, down 81% from Q1 2025.
  • Operating expenses rose to $2.7 million in Q1 2025, up 181% from Q1 2024.

Bottom Line

Alzamend is an early-stage biotech focused on brain health treatments. The company faces financial challenges but continues to develop new therapies for neurodegenerative and psychiatric diseases.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

6

CEO

Stephan Jackman

Website

www.alzamend.com

Headquarters

Atlanta, GA 30326, US

ALZN Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-177.48%

Return on Capital

-113.32%

Return on Assets

-174.22%

Earnings Yield

-3.57%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.60MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

3.80M

Volume

57.05K

Avg. Volume

145.95K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$7.03M

EBITDA

-$6.94M

Operating Cash Flow

-$5.96M

Capital Expenditure

-$210.00K

Free Cash Flow

-$6.17M

Cash & ST Invst.

$2.71M

Total Debt

$0.00

Alzamend Neuro Performance Analysis

Alzamend Neuro annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-04-30USD 0N/A
20232023-04-30USD 0N/A
20242024-04-30USD 0N/A
20252025-04-30USD 0N/A
Alzamend Neuro sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-04-30N/A
Q12025-07-31N/A
Q22025-10-31N/A
Q32026-01-31N/A
Alzamend Neuro annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-04-30USD -187.31N/A
20232023-04-30USD -205.9710.0%
20242024-04-30USD -132.33-35.8%
20252025-04-30USD -11.32-91.4%
Alzamend Neuro sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-04-30-42.9%
Q12025-07-3147.3%
Q22025-10-3176.6%
Q32026-01-31-93.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$4.60MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$657.67K

N/A

Employees

7

N/A

Net Income

-$2.20M

-111.6%

EBITDA

-$2.17M

-111.8%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

$2.71M

-19.2%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-1.74%

N/A

Return on Invested Capital

-3.22%

N/A

Free Cash Flow

-$1.74M

-22.0%

Operating Cash Flow

-$1.74M

-22.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
APREAprea Therapeutics, Inc.
$0.67-5.71%
BCDABioCardia, Inc.
$0.90+9.57%
CDIOCardio Diagnostics Holdings, Inc.
$1.63-5.23%
ADILAdial Pharmaceuticals, Inc.
$2.73-2.50%

Trending Stocks

Symbol / CompanyPricePrice Chg
ZYBTZhengye Biotechnology
$8.01+10.48%
AALAmerican Airlines Group
$15.14+0.01%
ACHRArcher Aviation
$5.31+0.20%
IRENIren
$40.20+0.20%

Questions About ALZN

What is the current price of Alzamend Neuro?

Alzamend Neuro is trading at $1.26 per share.

What is the 52-week range for Alzamend Neuro?

Over the past 52 weeks, Alzamend Neuro has traded between $0.84 and $3.35.

How much debt does Alzamend Neuro have?

As of the most recent reporting period, Alzamend Neuro reported total debt of $0.00.

How much cash does Alzamend Neuro have on hand?

Alzamend Neuro reported $2.71M in cash and cash equivalents in its most recent financial results.

What is Alzamend Neuro’s dividend yield?

Alzamend Neuro does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services